The global axial spondyloarthritis drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period (2022-2028). The market is primarily driven by favorable conditions for pharmaceutical producers and the attention of various government agencies on enhancing the current healthcare infrastructure. These will lead to a rise in global demand for various drugs for treatment options for axial spondyloarthritis in the near future. Additionally, significant investment in research and development, favorable reimbursement circumstances, and rising incidences and prevalence may all contribute to market growth. For instance, in March 2019, Certolizumab pegol (CIMZIA), a TNF inhibitor, has been approved by the US Food and Drug Administration for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA.) This is the first and only biologic medicine to be approved for nr-axSpA in the US, giving patients effective treatment who suffered from the condition access to a novel class of treatment.
Browse the full report description of “Global Axial Spondyloarthritis Drug Market Size, Share & Trends Analysis Report By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/axial-spondyloarthritis-drug-market
The majority of established key players in the global axial spondyloarthritis drug market are forming strategic agreements to improve their market position and expand their geographic reach. For instance, in January 2022, Amgen Inc. announced its research collaboration with Generate Biomedicines to find and develop protein therapies for five clinical targets in a variety of therapeutic areas and methodologies.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including AstraZeneca Plc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Novartis AG, Panacea Biotec Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Axial Spondyloarthritis Drug Market Report Segment
By Type
By Distribution Channel
Global Axial Spondyloarthritis Drug Market Report Segment by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/axial-spondyloarthritis-drug-market